Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia

Keyphrases

• Hypophosphatasia 100%
• Alpha Therapy 100%
• Asfotase Alfa 100%
• Pyridoxal 5′-phosphate 36%
• Treatment Period 27%
• Dual-energy X-ray Absorptiometry 18%
• Efficacy Index 18%
• Tissue-nonspecific Alkaline Phosphatase 18%
• 6-minute Walk Test 18%
• Statistical Significance 9%
• Adverse Events 9%
• No Significant Difference 9%
• Inorganic Pyrophosphate 9%
• Moderate to Severe 9%
• Enzyme Replacement Therapy 9%
• Potent Inhibitor 9%
• Histomorphometry 9%
• Bone Mineral Density 9%
• T-score 9%
• Muscle Strength 9%
• Distance Walked 9%
• Functional Capacity 9%
• Transiliac 9%
• Vitamin B6 9%
• Expected Range 9%
• Functional Disability 9%
• Alkaline Phosphatase Isoenzyme 9%
• Phosphate-P 9%
• Injection Site Reaction 9%
• EudraCT 9%
• Min-max 9%
• Alkaline Phosphatase Substrate 9%
• Gross Motor Function 9%
• Treatment Control 9%
• Lag Time 9%
• Density Results 9%
• Pediatric Onset 9%
• Well Tolerated 9%
• Change from Baseline 9%
• Circulating Forms 9%
• Period Change 9%
• Subject Change 9%

Medicine and Dentistry

• Hypophosphatasia 100%
• Asfotase Alfa 100%
• Adolescence 100%
• Pyridoxal 5 Phosphate 36%
• Dual-Energy X-Ray Absorptiometry 18%
• Mineralization 18%
• Six Minute Walk Test 18%
• Pediatrics 9%
• Morphometrics 9%
• Enzyme Replacement Therapy 9%
• Bone Density 9%
• Alkaline Phosphatase 9%
• Motor Performance 9%
• Muscle Strength 9%
• Alkaline Phosphatase Isoenzyme 9%
• Pyrophosphate 9%
• Injection Site Reaction 9%
• Pyridoxine 9%
• Dicholine Suberate 9%
• Adverse Event 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Hypophosphatasia 100%
• Asfotase Alfa 100%
• Pyridoxal 5 Phosphate 36%
• Adverse Event 9%
• Replacement Therapy 9%
• Alkaline Phosphatase 9%
• Enzymes 9%
• Pyrophosphate 9%
• Injection Site Reaction 9%
• Pyridoxine 9%
• Alkaline Phosphatase Isoenzyme 9%
• Dicholine Suberate 9%